MicroRNA-146a mitigates inflammation in T2DM by targeting interleukin-1 receptor-associated kinase 1 (IRAK1)/TNF receptor-associated factor 6 (TRAF6), thereby reducing inflammatory cytokine production and regulating the genes involved in the pathogenesis of T2DM [61]. This evidence concerns the gene IRAK1 and type 2 diabetes mellitus.